The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: Implications for preventing GVHD

Bone Marrow Transplantation

Volumn 47, Issue 7, 2012, Pages 967-980

  Chen, X ^a   Chang, C H ^b   Stein, R ^a   Goldenberg, D M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IMMUNOMEDICS INC   (United States)

Author keywords

antigen presenting cells; dendritic cells; GVHD; HLA DR; monoclonal antibody

Indexed keywords

HLA DR ANTIGEN; IMMU 114; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CD25+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MONOCYTE; MYELOID DENDRITIC CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGEN-PRESENTING CELLS; APOPTOSIS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-DR ANTIGENS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 84863723190     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.203     Document Type: Article

References (59)

1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389.
2. Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009; 114: 4327-4336.
3. Landfried K, Wolff D, Holler E. Pathophysiology and management of graft-versus-host disease in the era of reduced-intensity conditioning. Curr Opin Oncol 2009; 21: S39-S41.
4. Chakraverty R, Robinson S, Peggs K, Kottaridis PD, Watts MJ, Ings SJ et al. Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 827-834.
5. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005; 366: 733-741.
6. Hartwig UF, Nonn M, Khan S, Meyer RG, Huber C, Herr W. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant 2006; 37: 297-305.
7. Davies JK, Koh MB, Lowdell MW. Antiviral immunity and Tregulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biol Blood Marrow Transplant 2004; 10: 259-268.
8. Montagna D, Yvon E, Calcaterra V, Comoli P, Locatelli F, Maccario R et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 1999; 93: 3550-3557.
9. van Dijk AM, Kessler FL, Stadhouders-Keet SA, Verdonck LF, de Gast GC, Otten HG. Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br J Haematol 1999; 107: 169-175.
10. Caruso A, Licenziati S, Corulli M, Canaris AD, De Francesco MA, Fiorentini S et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 1997; 27: 71-76.
11. Amrolia PJ, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder ED et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003; 102: 2292-2299.
12. Samarasinghe S, Mancao C, Pule M, Nawroly N, Karlsson H, Brewin J et al. Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood 2010; 115: 396-407.
13. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
14. Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood 2007; 110: 9-17.
15. Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004; 172: 7393-7398.
16. Durakovic N, Bezak KB, Skarica M, Radojcic V, Fuchs EJ, Murphy GF et al. Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol 2006; 177: 4414-4425.
17. Koyama M, Hashimoto D, Aoyama K, Matsuoka K, Karube K, Niiro H et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. Blood 2009; 113: 2088-2095.
18. Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004; 10: 987-992.
19. Markey KA, Banovic T, Kuns RD, Olver SD, Don AL, Raffelt NC et al. Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood 2009; 113: 5644-5649.
20. Merad M, Hoffmann P, Ranheim E, Slaymaker S, Manz MG, Lira SA et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10: 510-517.
21. Zhang Y, Shlomchik WD, Joe G, Louboutin JP, Zhu J, Rivera A et al. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol 2002; 169: 7111-7118.
22. Wilson J, Cullup H, Lourie R, Sheng Y, Palkova A, Radford KJ et al. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med 2009; 206: 387-398.
23. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009; 114: 4919-4927.
24. Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 2010; 51: 376-389.
25. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
26. Arai S, Miklos DB. Rituximab in hematopoietic cell transplantation. Expert Opin Biol Ther 2010; 10: 971-982.
27. van Dorp S, Pietersma F, Wölfl M, Verdonck LF, Petersen EJ, Lokhorst HM et al. Rituximab treatment before reducedintensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transplant 2009; 15: 671-678.
28. Christopeit M, Schütte V, Theurich S, Weber T, Grothe W, Behre G. Rituximab reduces the incidence of acute graftversus-host disease. Blood 2009; 113: 3130-3131.
29. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D et al. Rituximab for steroid-refractory chronic graft-versushost disease. Blood 2006; 108: 756-762.
30. Carella AM, Biasco S, Nati S, Congiu A, Lerma E. Rituximab is effective for extensive steroid-refractory chronic graft-vshost-disease. Leuk Lymphoma 2007; 48: 623-624.
31. Bates JS, Engemann AM, Hammond JM. Clinical utility of rituximab in chronic graft-versus-host disease. Ann Pharmacother 2009; 43: 316-321.
32. Arpinati M, Chirumbolo G, Saunthararajah Y, Stanzani M, Bonifazi F, Bandini G et al. Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors. Biol Blood Marrow Transplant 2007; 13: 228-234.
33. Arpinati M, Chirumbolo G, Nicolini B, Agostinelli C, Rondelli D. Selective apoptosis of monocytes and monocytederived DCs induced by bortezomib (Velcade). Bone Marrow Transplant 2009; 43: 253-259.
34. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 8120-8125.
35. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404-406.
36. Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100: 1715-1720.
37. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003; 101: 1422-1429.
38. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
39. Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
40. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
41. Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood 2006; 108: 2736-2744.
42. Stein R, Gupta P, Chen X, Cardillo TM, Furman RR, Chen S et al. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyper-activation of ERK and JNK MAP kinase signaling pathways. Blood 2010; 115: 5180-5190.
43. Sharkey RM, Juweid M, Shevitz J, Behr T, Dunn R, Swayne LC et al. Evaluation of a complementarity-determining regiongrafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995; 55: 5935s-5945s.
44. Stein R, Balkman C, Chen S, Rassnick K, McEntee M, Page R et al. Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. Leuk Lymphoma 2011; 52: 273-284.
45. Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007; 47: 1119-1128.
46. Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 2001; 249: 99-110.
47. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 165: 6037-6046.
48. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184: 39-51.
49. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586-2591.
50. Amet N, Gacad M, Petrosyan A, Pao A, Jordan SC, Toyoda M. In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction. Transpl Immunol 2010; 23: 170-173.
51. Sato T, Deiwick A, Raddatz G, Koyama K, Schlitt HJ. Interactions of allogeneic human mononuclear cells in the twoway mixed leucocyte culture (MLC): influence of cell numbers, subpopulations and cyclosporin. Clin Exp Immunol 1999; 115: 301-308.
52. Martins SL, St John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 2004; 104: 3429-3436.
53. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005; 35: 225-231.
54. Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD and immune reconstitution. Blood 2010; 116: 3080-3088.
55. Li H, Kaplan DH, Matte-Martone C, Tan HS, Venkatesan S, Johnson K et al. Langerhans cells are not required for graftversus-host disease. Blood 2011; 117: 697-707.
56. Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood 2004; 103: 1140-1146.
57. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011; 117: 1061-1070.
58. Richter WF, Gallati H, Schiller CD. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos 1999; 27: 21-25.
59. Munster DJ, MacDonald KP, Kato M, Hart DJ. Human T lymphoblasts and activated dendritic cells in the allogeneic mixed leukocyte reaction are susceptible to NK cell-mediated anti-CD83-dependent cytotoxicity. Int Immunol 2004; 16: 33-42.